MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
0.5410
-0.0370
-6.40%
Closed 19:15 03/26 EDT
OPEN
0.5800
PREV CLOSE
0.5780
HIGH
0.5800
LOW
0.5200
VOLUME
189.43K
TURNOVER
0
52 WEEK HIGH
6.19
52 WEEK LOW
0.5200
MARKET CAP
47.76M
P/E (TTM)
-1.7446
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTOR last week (0316-0320)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/18 12:05
Weekly Report: what happened at CTOR last week (0309-0313)?
Weekly Report · 03/16 10:23
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA)
TipRanks · 03/13 12:50
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
TipRanks · 03/10 13:28
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
TipRanks · 03/10 12:58
Citius Oncology Announces Data From Phase 1 Clinical Study Of Direct T-Regulatory Cell Depletion Activity Of LYMPHIR Shows 24% Objective Response Rate, 48% Clinical Benefit Rate In Participants With Recurrent Or Refractory Gynecologic Cancers
Benzinga · 03/10 12:49
Weekly Report: what happened at CTOR last week (0302-0306)?
Weekly Report · 03/09 10:24
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.